At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAOV NanoVibronix Inc
Pre-Market Trading 11-26 09:00:44 EST
0.6880
-0.0181
-2.56%
High0.7400
Low0.6340
Vol93.16K
Open0.7399
D1 Closing0.7061
Amplitude15.01%
Mkt Cap2.58M
Tradable Cap2.31M
Total Shares3.75M
T/O65.02K
T/O Rate2.78%
Tradable Shares3.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.